While the news on patients hospitalized with COVID-19 was not as hoped, the ability to positively impact outcomes when identified early is promising.

Eli Lilly Chairman and CEO Dave Ricks told CNBC on Tuesday that he believes the company’s coronavirus antibody treatment will still be beneficial to Covid-19 patients, despite the recent end to a study of the drug in a hospital setting.

To watch the interview, click here.

Bio Link Partner and former Humana & Anthem executive Kristine Seymour leads the Michael Best Strategies’ Healthcare Innovation Group. She works with start-ups and innovative healthcare clients to find a pathway to revenue, build revenue, optimize business strategy, and navigate the complex healthcare ecosystem. Expertise: Healthcare Market Development, Business Growth Strategy, Sales & Distribution, and Healthcare Start-ups and Innovation